Study on Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors
Sponsor: Merck Sharp & Dohme LLC
Sponsor score: 40
ClinicalTrials ID:NCT06395103
This clinical trial is testing the safety and effectiveness of a new drug, zilovertamab vedotin, in children and young adults with certain types of blood cancers and solid tumors that have not responded to previous treatments.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is part of a larger research project and focuses on evaluating how well the drug zilovertamab vedotin works and how safe it is for children with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, or neuroblastoma. It also includes young adults with Ewing sarcoma.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with specific blood cancers like B-precursor B-ALL or DLBCL/Burkitt lymphoma.
- Diagnosed with solid tumors such as neuroblastoma or Ewing sarcoma.
Exclusion Criteria
- History of organ transplant.
- Serious heart disease.
- Liver cirrhosis.
- Severe nerve damage.
- Certain genetic nerve disorders.
- Down syndrome.
- Ongoing graft-versus-host disease or treatment for it.
- HIV infection.
- Allergic to any part of the study drug.
- Recent radiation therapy within 4 weeks before starting the study.
- Long-term steroid use above a certain dose.
- Use of certain medications that affect liver enzymes within a specific time before the study.
- Recent cancer treatments or experimental drugs within 4 weeks before the study.
- Recent live vaccines within 30 days before the study.
- Other active cancers needing treatment in the past year.
- Active infections needing treatment.
- Hepatitis B or C infection.
- Not fully recovered from major surgery.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Yale-New Haven Hospital ( Site 1012) | 06510 | New Haven | Connecticut |
| Johns Hopkins All Children's Hospital ( Site 1025) | 33701 | Saint Petersburg | Florida |
| University of Iowa-Holden Comprehensive Cancer Center ( Site 1017) | 52242 | Iowa City | Iowa |
| Children's Mercy Hospital ( Site 1024) | 64108 | Kansas City | Missouri |
| Rutgers Cancer Institute of New Jersey ( Site 1008) | 08903 | New Brunswick | New Jersey |
| New York Medical College ( Site 1023) | 10595 | Valhalla | New York |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003) | 58122 | Fargo | North Dakota |
| Children's Hospital of Philadelphia (CHOP) ( Site 1021) | 19104 | Philadelphia | Pennsylvania |
| Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015) | 57105 | Sioux Falls | South Dakota |
| University of Texas MD Anderson Cancer Center ( Site 1007) | 77030 | Houston | Texas |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.